Genzyme Corp.'s longstanding legal dispute with some shareholders over the buyback of Genzyme Biosurgery stock in 2003 will end not with a figurative bang but with a $64 million whimper, if a judge approves an agreement made between the parties. (BioWorld Today) Read More
